Capivasertib

Generic Name
Capivasertib
Brand Names
Truqap
Drug Type
Small Molecule
Chemical Formula
C21H25ClN6O2
CAS Number
1143532-39-1
Unique Ingredient Identifier
WFR23M21IE
Background

Capivasertib has been investigated for the treatment of Metastatic Breast Cancer.

Associated Conditions
-
Associated Therapies
-
koreabiomed.com
·

AstraZeneca launches Truqap as Korea's 1st AKT inhibitor for breast cancer patients

AstraZeneca Korea launched Truqap, the first AKT inhibitor for HR+/HER2- breast cancer, targeting PIK3CA, AKT1, or PTEN mutations. Truqap, approved in April, offers new hope for patients progressing after endocrine therapy. The CAPItello-291 study showed Truqap plus fulvestrant doubled median progression-free survival to 7.3 months. Despite financial concerns over NGS costs, global guidelines recommend mutation testing for effective treatment.
astrazeneca.com
·

Enhertu showed substantial clinical activity in patients with HER2-positive metastatic breast

Post-hoc analysis in DESTINY-Breast12 showed CNS ORR of 82.6% in patients without prior CNS therapy and 50.0% in those with prior therapy. Safety profiles of Enhertu were consistent with previous trials, with no new concerns. ILD/pneumonitis rates were 12.9% and 16.0% in patients without and with brain metastases, respectively, with most events being low grade.
biopharmadive.com
·

Relay breast cancer drug shows potential in early trial

Relay Therapeutics' experimental breast cancer drug, RLY-2608, delayed tumor growth by 9 months in a trial, shrinking tumors in 75% of participants. The drug, targeting PI3Ka mutations, showed potential to replace existing treatments with less toxicity, prompting Relay to plan a pivotal trial for 2024. The study enrolled 118 patients with PI3Ka-mutated, HR-positive, HER2-negative breast cancer.
© Copyright 2024. All Rights Reserved by MedPath